Nisa Investment Advisors
VIRX

Nisa Investment Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Nisa Investment Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,800
Closed -$43 – 2340
2021
Q2 		$43 Buy
+3,800
New +$38.1K ﹤0.01% 1980

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nisa Investment Advisors's VIRX Position: Q3 2021 in Review

Nisa Investment Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2021, closing a stake of 3,800 shares — an estimated $43 sold.

Nisa Investment Advisors first reported a position in VIRX in Q2 2021 and held it in 1 quarter. The position peaked at $43 in Q2 2021. 68 funds tracked by Wall St. Rank hold VIRX as of Q3 2021.

  • Nisa Investment Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Nisa Investment Advisors sold 3,800 Viracta Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $43.
  • Nisa Investment Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Nisa Investment Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $43 in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Nisa Investment Advisors's 13F filing for Q3 2021, filed 18 Oct 2021.